Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yttrium-90 Ibritumomab Tiuxetan with High-Dose Chemotherapy and AHSCT for Relapsed B-Cell NHL
NCT00562978Phase 2Completed
- Sponsor
- City of Hope
- Start
- May 2000
- Primary completion
- May 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of ibritumomab tiuxetan in B-cell non-Hodgkin lymphoma (B-NHL) (2 arms), sponsored by City of Hope. Primary endpoints: Number of Patients Achieving Complete Response at 5 years, Number of Patients With Grade 3 or Greater Toxicity at 100 days and 2 more. Started May 2000; status: completed.
02
Drugs
ibritumomab tiuxetan
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT00562978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562978.